Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Jan 15, 2005 (Vol. 25, No. 2)

BioScreening.com: Drug Discovery Portal

  • Interesting coverage
  • A bit removed from information
Drugs are big business, and where there is money, there are a lot of companies pursuing it. A section of the drug business focuses on drug discovery providing the beat for BioScreening.com, which offers a portal on the subject. Visitors to the site will recognize the commercial nature of the site with prominent advertisements across the top of the opening page. Beneath that is an untidy collection of information in three categories: WebDirectory, News/Press Releases, and Conference Information. Subcategories in the WebDirectory section are abundant in links to sites of companies and general information, but decidedly lacking in direct connections to information, which is frequently a few clicks away (oftentimes requiring registration).
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »